Sova will focus our internal clinical plan on therapies supported by the mechanism, our preclinical findings, and the development of compounds reported to act on the molecular targets of H2S. Such indications could include postherpetic neuralgia, chemotherapy induced peripheral neuropathic pain (CIPN pain) and diabetic neuropathy.

The mechanism and our preclinical findings also support large-market indications, such as osteoarthritis, rheumatoid arthritis, neuropathic pain and migraine, that we would seek to develop with a strategic partner.